PLAINSBORO, N.J., Oct. 4, 2010 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today the launch of the Integra™ Endoscopic Gastroc Release (EGR) System in the United States. Integra’s EGR System is a disposable device with a unique articulating blade that allows selective cutting of soft tissues. It is intended for use in the surgical treatment for posterior heel cord, or equinus, contracture.
“We are very pleased to offer this exciting new addition to our lower extremity product line. The retractable blade technology is an integrated system that allows surgeons to control the position of the blade and limit the uncertainty in determining exactly which tissues to cut,” said Pete Ligotti, Vice President of Sales and Marketing for Integra Extremity Reconstruction. “We also plan to expand this product line with the release of additional sizes.”
Equinus contracture is a condition that limits ankle motion, frequently due to contraction or tightness of the calf muscle. Surgical treatment involves recession of selected tissues of the calf muscle (composed of the gastrocnemius and soleus muscle complex). Traditionally performed as an open procedure, the recession of the gastrocnemius aponeurosis can be performed endoscopically through a small incision. This is a minimally invasive, less traumatic procedure that produces a smaller and less apparent scar.
Gastrocnemius recession is being used increasingly as a component in the surgical treatment of posterior tibial tendon dysfunction (PTTD), diabetic forefoot ulcers, symptomatic acquired flatfoot, and hallux valgus.
The EGR System will be sold by Integra’s Extremity Reconstruction sales organization, which focuses on lower extremity fixation, upper extremity fixation, tendon protection, peripheral nerve repair/protection and wound repair.
Integra LifeSciences, a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedics, neurosurgery, spine, reconstructive and general surgery.
For more information, please visit www.integralife.com
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of the Integra™ Endoscopic Gastroc Release System. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use this products may affect the prospects for its use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the heading “Risk Factors” included in Item IA of Integra’s Annual Report on Form 10-K for the year ended December 31, 2009 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
Integra LifeSciences Holdings Corp IART-P
CONTACT: Integra LifeSciences Holdings Corp.
Gianna Sabella, Director, Corporate Communications
(609) 936-2389
gianna.sabella@integralife.com
